Stock PCRX PACIRA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
30.33 USD -0.43% Intraday chart for Pacira BioSciences, Inc. +2.16% -10.11%
May. 14 Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
May. 10 Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.125% CONVERTIBLE SENIOR NOTES DUE 2029
Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating
Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024
Pacira BioSciences : 1Q 2024 Earnings Presentation
Pacira: Q1 Earnings Snapshot
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares.
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Pacira BioSciences, Inc. authorizes a Buyback Plan.
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCRX Stock
  4. News Pacira BioSciences, Inc.
  5. Other languages